PROGRAMME EHMSG Workshop
Friday, September 13, 2024
08.25 – 08.30 hrs | Welcome by EHMSG President José Machado
08.30 – 10.30 hrs | Session 1: Hot topics in H.pylori and gut microbiota
Chair: Jose Machado, Porto, Portugal & Ari Ristimäki, Helsinki, Finland
08.30 – 08.50 hrs
1.1. The person-to-person transmission landscape of the gut and oral microbiomes
Vitor Heidrich, Italy
08.50 – 09.10 hrs
1.2. New drugs targeting H. pylori envelopes
Ivo Boneca, France
09.10 – 09.30 hrs
1.3. Evolving concepts in H. pylori management
Shailja Shah, United States
09.30 – 09.50 hrs
1.4. Vaccination Protects Against Gastric Cancer
Thomas Boren, Umea, Sweden
09.50 – 10.10 hrs
1.5. The humanized Leb mouse model reproduces the Correa gastric cancer cascade during the chronic H. pylori infection
Artem Piddubnyi, Umea, Sweden
10.10 – 10.30 hrs
1.6. GWAS on H. pylori seroprevalence
Constanza Camargo, Rockville, MD, United States
10.30 – 11.00 hrs | Coffee Break
11.00 – 12.45 hrs | Session 2: News on gastritis (Parallel Session)
Chair: Theodore Rokkas, Athens, Greece & Fatima Carneiro, Porto, Portugal
11.00 – 11.20 hrs
02.01 The RE.GA.IN consensus project
Massimo Rugge, Italy
11.20 – 11.40 hrs
02.02 Autoimmune gastritis: long-term natural history in naïve Helicobacter pylori-negative patients
Ludovica Bricca, Italy
11.40 – 12.00 hrs
02.03 Trends in the prevalence of atrophic gastritis and Helicobacter pylori in Far East
Yoshio Yamaoka, Japan
12.00 – 12.15 hrs
02.04 Helicobacter pylori Seroprevalence In Histologically H. pylori-Negative Autoimmune Atrophic Gastritis Patients
Edith Lahner, Rome, Italy
12.15 – 12.30 hrs
02.05. Interleukin‐27 Is Highly Expressed In The Serum And Gastric Mucosa Of Children With H. pylori‐Associated Gastroduodenal Diseases
Dulciene Queiroz, Belo Horizonte, Brasil
12.30 – 12.45 hrs
02.06 Autoimmune Gastritis In Pediatric Age And Its Relationship With H. pylori Infection
Inês Aires Martins, Porto, Portugal
11.00 – 12.45 hrs |Session 3: Microbiome mechanisms of action (Parallel Session)
Chair: Mirjana Rajilic-Stojanovic, Belgrade, Serbia & Rui Ferreira, Porto, Portugal
11.00 – 11.20 hrs
03.01 Protein fermentation products and health outcomes
Silvio Waschina, Kiel, Germany
11.20 – 11.40 hrs
03.02 Mechanisms of microbiome engraftment
Gianluca Ianiro, Italy
11.40 – 12.00 hrs
03.03 Mycobiome in IBD
Petra Bacher, Germany
12.00 – 12.15 hrs
03.04 Microbiome Composition In Patients With Upper Gastrointestinal Cancer And Small Intestinal Bacterial Overgrowth (SIBO)
Marino Venerito, Magdeburg, Germany
12.15 – 12.30 hrs
03.05. The Impacts Of The Crosstalk Between Bacterial Vaginosis Associated Bacteria And Trichomonas Vaginalis On The Pathogenesis And Host Immune Responses
Shu-Fang Chiu, Taipei, Taiwan
12.30 – 12.45 hrs
03.06 Mycobiome Dysbiosis In Liver Cirrhosis Patients
Darja Nikitina, Kaunas, Lithuania
12.45 – 14.00 hrs | Lunch Break & Poster Viewing
14.00 – 15.00 hrs | Session 4: Industry-Sponsored Satellite Symposium
Chair: Colm O’Morain, Dublin, Ireland & Peter Malfertheiner, Munich, Germany
Click HERE for details
15.00 – 16.45 hrs | Session 5: Helicobacter pylori: Genetics and Beyond (Parallel Session)
Chair: Peter Malfertheiner, Munich, Germany & Celso Reis, Porto, Portugal
15.00 – 15.20 hrs
05.01 Differences in H. pylori population structures worldwide
Kaisa Thorell, Sweden
15.20 – 15.40 hrs
05.02 H. pylori evolution depends on niche specific physiological conditions
Sebastian Suerbaum, Germany
15.40 – 16.00 hrs
05.03 Impact of H. pylori on mucosal immunity and colorectal cancer
Markus Gerhard, Germany
16.00 – 16.15 hrs
05.04 Helicobacter pylori Infection Leads To Systemic Metabolic Reprogramming Through The Il-6/JAK/STAT3 Pathway
Bingting Yu, Rotterdam, Netherlands
16.15 – 16.30 hrs
05.05 The H. pylori Autotransporter ImaA Associates With Extracellular Vesicles To Modulate Host Inflammatory Responses In Gastric Epithelial Cells
Angus Cramond, Clayton, Australia
16.30 – 16.45 hrs
05.06 The Prophages Of The Helicobacter Genus
Filipa Vale, Lisbon, Portugal
15.00 – 16.45 hrs | Session 6: Oncobiome (Parallel Session)
Chair: Juozas Kupcinskas, Kaunas, Lithuania & Carina Pereira, Porto, Portugal
15.00 – 15.20 hrs
06.01 Microbiome mediated inflammation in colon cancer
Mathias Chamaillard, Lille, France
15.20 – 15.40 hrs
06.02 Predicting CRC survival post-surgical resection using tumour microbial profiling
James Alexander, United Kingdom
15.40 – 16.00 hrs
06.03 Microbiota-modulated immune checkpoint
Carolina Alves Costa Silva, France
16.00 – 16.15 hrs
06.04 Longitudinal Definition Of The Gastric Microbiome From A High-Gastric-Cancer-Risk Cohort From Colombia, South America
Anthony Mannion, United States
16.15 – 16.30 hrs
06.05 Characterization Of The Intratumoral Microbiota In Gastric Cancer Patients
Marine Jauvain, Bordeaux, France
16.30 – 16.45 hrs
06.06 Microbiome-Derived Metabolites As Novel Biomarkers Of Gastric Cancer
Rui Ferreira, Porto, Portugal
16.45 – 17.15 hrs | Coffee Break
17.15 – 19.00 hrs | Session 7: Gastric Carcinogenesis (Parallel Session)
Chair: Emilie Bessède, Bordeaux, France & Carla Oliveira, Porto, Portugal
17.15 – 17.35 hrs
07.01 Microbiome and gastric cancer
Ceu Figueiredo, Portugal
17.35 – 17.55 hrs
07.02 Gastric Intestinal Metaplasia an Innocent Bystander in Gastric Cancer?
Ken Sugano, Japan
17.55 – 18.15 hrs
07.03 Natural History of Sporadic and Hereditary Diffuse Gastric Carcinoma: From Onset to Progression
Fatima Carneiro, Portugal
18.15 – 18.30 hrs
07.04 Unveiling Plasma Protein Signatures For Gastric Preneoplasia And Cancer Lesion Detection
Eliette Touati, Paris, France
18.30 – 18.45 hrs
07.05 Gastric Cancer Invasion: Physical And Biochemical Nuclear Readouts Elicited By E-Cadherin Loss
Joana Figueiredo, Porto, Portugal
18.45 – 19.00 hrs
07.06 The Autophagy Protein IRGM Is A Key Player In Gastric Carcinogenesis
Elsa Kalluzhathil, Kensington, Australia
17.15 – 19.00 hrs | Session 8: FMT Session (Parallel Session)
Chair: Josbert Keller, Den Haag, Netherlands & Gianluca Ianiro, Rome, Italy
17.15 – 17.35 hrs
08.01 Safety in FMT
Josbert Keller, Netherlands
17.35 – 17.55 hrs
08.02 Regulation of FMT and donor screening
Christian Hvas, Denmark
17.55 – 18.15 hrs
08.03 How to improve FMT success
Alexander Link, Germany
15.15 – 18.30 hrs
08.04 Effectiveness Of Fecal Microbiota Transplant In Metabolic Syndrome: A Randomized Double-Blinded Placebo-Controlled Trial
Ratha-korn Vilaichone, Pathumthani,Thailand
18.30 – 18.45 hrs
08.05 Fecal Microbiota Transplantation (FMT) Versus Placebo In Patients Receiving Pembrolizumab Plus Axitinib For Advanced Renal Cell Carcinoma. A Double-Blind Randomized Controlled Trial (TACITO Trial)
Gianluca Ianiro, Rome, Italy
18.45 – 19.00 hrs
08.06 Efficacy And Safety Of Fecal Microbiota Transplantation In Patients With Irritable Bowel Syndrome: A Preliminary Report
Ho-Kyoung Lee, Seoul, Republic of Korea
20.00 hrs
EHMSG Conference Dinner
Saturday, September 14, 2024
08.30 – 09.15 hrs | Session 9: Memorial Talks
Chair: Francis Mégraud, Bordeaux, France & Colm O’Morain, Dublin, Ireland & Peter Malfertheiner, Munich, Germany
08.30 – 08.45 hrs
09.01 In Memoriam Ashley Price
Anthony Axon, United Kingdom
08.45 – 09.00 hrs
09.02 In Memoriam Pentti Sipponen
Ari Ristimäki, Finland
09.00 – 09.15 hrs
09.03 In Memoriam Adrian Lee
Jim Fox, United States
09.15 – 11.00 hrs | Session 10: H. pylori management (Parallel Session)
Chair: Colm O’Morain, Dublin, Ireland & Nuno Almeida, Coimbra, Portugal
09.15 – 09.35 hrs
10.01 Current role of tailored therapy in treating H. pylori infection
Theodore Rokkas, Greece
09.35 – 09.55 hrs
10.02 The rebirth of Bismuth in H. pylori eradication
Rocco Maurizio Zagari, Italy
09.55 – 10.15 hrs
10.03 Latin American Registry on the Management of H. pylori Infection (Hp-LATAMReg)
Arnoldo Riquelme, Chile
10.15 – 10.30 hrs
10.04 Effectiveness And Safety Of First-Line Empirical Non-Bismuth Concomitant Therapy Versus Single-Capsule Bismuth Quadruple Therapies In Spain: Analysis Of 12,000 Patients From The European Registry On Helicobacter pylori Management (Hp-Eureg)
Olga Nyssen, Madrid, Spain
10.30 – 10.45 hrs
10.05 A Novel Multi-Epitope-Based Vaccine Against H. pylori; Evaluation Of The Protective Effect
Behnam Kalali, Munich, Germany
10.45 – 11.00 hrs
10.06 7-Day Therapy Vs. 14-Day Therapy In Empirical And Tailored Therapy: A Placebo-Controlled Randomized Nationwide Trial In Korea
Byung-Wook Kim, Incheon, Republic of Korea
09.15 – 11.00 hrs | Session 11: Probiotics (Parallel Session)
Chair: Francesco Franceschi, Rome, Italy & Christian Schulz, Munich, Germany
09.15 – 09.35 hrs
11.01 Use of probiotics in chronic liver diseases
Alexander Link, Germany
09.35 – 09.55 hrs
11.02 Inflammatory bowel diseases: when can probiotics be helpful?
Loris Lopetuso, Italy
09.55 – 10.15 hrs
11.03 Dietary Sulforaphane Increases Butyrate-Producing Intestinal Microbiota And Decreases Fecal Calprotectin Level In Patients With Ulcerative Colitis
Akinori Yanaka, Tsukuba, Japan
10.15 – 10.30 hrs
11.04 The Beneficial Effect Of A Probiotic Intervention On Quality Of Sleep - A Randomized, Double-Blinded, Placebo-Controlled Study
Angela Horvath, Graz, Austria
10.30 – 10.45 hrs
11.05 Bifidobacterium Modulates The Immune Response In A Microsatellite Instability Colorectal Cancer Mouse Model
Patricia Vieira, Porto, Portugal
10.45 – 11.00 hrs
11.06 Bacterial Genotoxins Trigger Invadosome Formation Associated To Matrix Degradation
Lamia Azzi-Martin, Bordeaux, France
11.00 – 11.30 hrs | Coffee Break
11.30 – 13.30 hrs | Session 12: Debates – Gastric cancer screening
Chair: Marcis Leja, Riga, Latvia & Miguel Areia, Coimbra, Portugal
11.30 – 11.50 hrs
12.01 Optimal strategies for gastric cancer screening – targeted vs. population based
Iris Lansdorp Vogelaar, Netherlands
11.50 – 12.10 hrs
12.02 What is the optimal age for screening?
Jan Bornschein, United Kingdom
12.10 – 12.30 hrs
12.03 Is there a role for endoscopy and AI in gastric cancer screening
Mario Dinis Ribeiro, Portugal
12.30 – 12.50 hrs
12.04 Gastric cancer screening experience in Japan
Hidekazu Suzuki , Japan
12.50 – 13.10 hrs
12.05 Helicobacter pylori Treatment and Gastric Cancer Risk After Endoscopic Resection of Dysplasia: A Nationwide Cohort Study
Hae Won Yoo, Korea
13.10 – 13.30 hrs
12.06 Helicobacter pylori treatment and risk of gastric cancer in large intervention trials in China
Wen Qing Li, China
13.30 – 15.00 hrs | Lunch Break & Poster Viewing
15.00 – 17.00 hrs |Session 13: Updates in Helicobacter & Microbiota
Chair: Annemieke Smet, Antwerp, Belgium & Ceu Figueiredo, Porto, Portugal
15.00 – 15.20 hrs
13.01 Million Microbiome from Humans Project
Lars Engstrand, Sweden
15.20 – 15.40 hrs
13.02 Cortactin-dependent control of Par1b-regulated epithelial cell polarity in Helicobacter pylori Infection
Steffen Backert, Erlangen, Germany
15.40 – 16.00 hrs
13.03 Effect of faecal microbiota transplantation on multidrug-resistant bacteria and the resistome
Elizabeth Terveer, The Netherlands
16.00 – 16.20 hrs
13.04 The potential utility of chitosan micro/nanoparticles in the treatment of gastric infection
Cristina Martins, Portugal
16.20 – 16.40 hrs
13.05 Novel principles for cure of H. pylori infection
Peter Malfertheiner, Germany
16.40 – 17.00 hrs
13.06 Histamine Signaling Is Essential for Tissue Macrophage Differentiation and Suppression of Bacterial Overgrowth in the Stomach Cell
Ki Taek Nam, Korea
17.00 – 18.00 hrs | Session 14: Closing Session
Chair: José Machado, Porto, Portugal & Francis Mégraud, Bordeaux, France
17.00 – 17.20 hrs
14.01 Awarding of the Marshall and Warren Medal 2024 to Fatima Carneiro, Porto, Portugal
17.20 – 17.35 hrs
14.02 Awarding of the EHMSG Oral and Poster Awards
17.35 – 17.50 hrs
14.03 Presentation of the EHMSG Journal
Francesco Franceschi, Italy
17.50 – 18.00 hrs
14.04 Presentation of the next meeting in Rome, Italy
Gianluca Ianiro, Italy
Closing Remarks